Profile Picture


Organizational Units

Organizational Unit

Job Title

First Name


Last Name



Email Address

Birth Date

Search Results

Now showing 1 - 5 of 5
  • Publication
    Circulating furin, IL-6, and presepsin levels and disease severity in SARS-CoV-2-infected patients
    (2021-06-01T00:00:00Z) Kocyigit, Abdurrahim; Sogut, Ozgur; Kanimdan, Ebru; Guler, Eray Metin; Kaplan, Onur; Eren, Canan; Ozman, Zeynep; Yasar, Oznur; KOÇYİĞİT, ABDÜRRAHİM; BALKAN, EZGİ; KANIMDAN, EBRU; YENİGÜN, VILDAN BETÜL; ÖZMAN, ZEYNEP
    Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a vast number of infections and deaths that deeply affect the world. When the virus encounters the host cell, it binds to angiotensin-converting enzyme 2, then the S protein of the virus is broken down by the transmembrane protease serine 2 with the help of furin, allowing the virus to enter the cell. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome, may play a major role in the pathology of COVID-19. Therefore, the aim of this study is to investigate the relationship between circulating furin levels, disease severity, and inflammation in patients with SARS-CoV-2. A total of 52 SARS-CoV-2 patients and 36 healthy control participants were included in this study. SARS- CoV-2 patients were scored by the disease activity score. Serum furin, presepsin, and interleukin-6 (IL-6) levels were assessed using an enzyme-linked immunosorbent assay. The mean furin, presepsin, and IL-6 levels were significantly higher in the peripheral blood of SARS-CoV-2 compared to the controls (p < 0.001). There were close positive relationship between serum furin and IL-6, furin and presepsin, and furin and disease severity (r = 0.793, p < 0001; r = 0.521, p < 0.001; and r = 0,533, p < 0.001, respectively) in patients with SARS-CoV-2. These results suggest that furin may contribute to the exacerbation of SARS-CoV-2 infection and increased inflammation, and could be used as a predictor of disease severity in COVID-19 patients.
  • Publication
    Evaluation of Some Physico-chemical and Antioxidant Characteristics of Commercial Honey Samples Originated from Different Regions of Turkey
    (2022-01-01T00:00:00Z) Bilgin, Mehmet Gültekin; Güneş Bayır, Ayşe; Özman, Zeynep; Babalı Balıbey, Fatmanur; Turgay, Feyzanur; Karakaş, İrem; Köse, Nesrin; Sevinç, Tülay; Selçuk, Tuğbanur; Öztürk, Nezire; BİLGİN, MEHMET GÜLTEKİN; GÜNEŞ BAYIR, AYŞE; ÖZMAN, ZEYNEP; BABALI BALIBEY, FATMANUR
  • Publication
    Olive Leaf Extract Downregulates the Protein Expression of Key SARS-CoV-2 Entry Enzyme ACE-2, TMPRSS2, and Furin.
    (2024-06-04) Kocyigit A.; Kanimdan E.; Yenigun V. B.; Ozman Z.; Balıbey F. B.; Durmuş E.; Yasar O.; KOÇYİĞİT, ABDÜRRAHİM; YAŞAR, ÖZNUR; KANIMDAN, EBRU; YENİGÜN, VILDAN BETÜL; ÖZMAN, ZEYNEP; BABALI BALIBEY, FATMANUR
    Severe acute respiratory syndrome coronavirus 2 poses ongoing global health challenges due to its propensity for mutations, which can undermine vaccine efficacy. With no definitive treatment available, urgent research into affordable and biocompatible therapeutic agents is extremely urgent. Angiotensin converting enzyme-2 (ACEII), transmembrane protease serine subtype 2 (TMPRSS2), and Furin enzymes, which allow the virus to enter cells, are particularly important as potential drug targets among scientists. Olive leaf extract (OLE) has garnered attention for its potential against COVID-19, yet its mechanism remains understudied. In this study, we aimed to investigate the effects of OLE on ACEII, TMPRSS2, and Furin protein expressions by cell culture study. Total phenol, flavonoid content, and antioxidant capacity were measured by photometric methods, and oleuropein levels were measured by liquid LC-HR-MS. Cell viability was analyzed by ATP levels using a luminometric method. ACEII, TMPRSS2, and Furin expressions were analyzed by the Western Blotting method. ACEII, TMPRSS2, and Furin protein expression levels were significantly lower in dose dependent manner and the highest inhibition was seen at 100 ug/ml OLE. The results showed that OLE may be a promising treatment candidate for COVID-19 disease. However, further studies need to be conducted in cells co-infected with the virus.
  • Publication
    Comparative cell viability of dentin-bonding adhesive systems on human dental pulp stem cells: time-dependent analysis
    (2024-12-01) Kazak M.; Sarialioglu Gungor A.; ÖZMAN Z.; Donmez N.; ÖZMAN, ZEYNEP
    Background: Restorative materials are in prolonged contact with living tissues such as oral mucosa, dentin, pulp, periodontal, and periapical tissues. Therefore, the potentially harmful effects of these materials and their components on oral tissues should be evaluated before clinical use. This study aimed to compare the cell viability of different adhesive systems (ASs) on human dental pulp stem cells (hDPSCs). Methods: Three ASs that combining methacryloyloxydecyl dihydrogen phosphate (MDP) monomer with new hydrophilic amide monomers [Clearfil Universal Bond Quick(CUBQ), Kuraray Noritake], self-reinforcing 3D monomer [Bond Force II(BFII), Tokuyama)], and dual-cure property [Futurabond DC(FBDC), VOCO] were used. Three (n = 3) samples were prepared for each group. Dental pulp stem cells were isolated from ten patients' extracted third molar teeth. Samples were incubated in Dulbecco's modified Eagle's medium (DMEM) for 24 h (h), 72 h, and 7 days (d) to obtain extracts. For the control group, cells were cultured without DBA samples. Cell viability of ASs extracts was measured using a cell proliferation detection kit (WST-1, Roche). Statistical analysis was performed using two-way ANOVA and post-hoc (Duncan) tests (p < 0.05). Results: At 24 and 72 h statistically significant differences were determined between control and BFII, control and FBDC groups (p < 0.05), while no differences between control and CUBQ groups (p > 0.05). On the 7th d, statistically significant differences were found between the control and experimental groups (p < 0.05), while no differences between experimental groups (p > 0.05). A statistically significant difference was detected for the BFII group over the three-time interval (p < 0.05). The lowest cell viability was observed for the FBDC group at 24 h, and the difference was statistically significant when compared with 72 h and 7th d (p < 0.05). Conclusion: All ASs showed different cell viability values at various exposure times. It should be taken into consideration that pH values, as well as the contents of ASs, have a significant effect on the cell viability.
  • Publication
    Comparison of the effects of rutaecarpine on molecular subtypes of breast cancer
    (2021-06-01T00:00:00Z) Çokluk, Erdem; Özman, Zeynep; Güney, Gamze; Deveci, Asuman; Şekeroğlu, Mehmet Ramazan; ÖZMAN, ZEYNEP
    Objective: Natural compounds have gained considerable attention in recent years due to disadvantages and properties of current chemotherapy drugs in cancer therapy. In addition, the impact of these compounds is specific for each type and/or subtypes of cancer due to different treatment response. Rutaecarpine, an alkaloid obtained from Evodia Rutaecarpa Chinese herb, has anticancer activity by inhibiting topoisomerase and/or cyclo-oxygenase-2 levels. However, the effectiveness of rutaecarpine has not been well known in breast cancer in terms of subtype. Therefore, we investigated the potential therapeutic effects of rutaecarpine on two different subtypes of breast cancer cells. Materials and methods: The cytotoxic and apoptotic effects of rutaecarpine on MCF-7 and MDA-MB-231 cells were analyzed by WST-1, Annexin V, cell cycle, and acridine orange staining. Results: WST-1 results indicated that rutaecarpine significantly inhibited the growth of both cancer cells for 48 h (P < 0.05). In addition, rutaecarpine treatment caused apoptotic cell death through chromatin condensation and nuclear blebbing and G0/G1 arrest in both breast cancer cells. However, the efficacy of rutaecarpine was more profound in MCF-7 cells than MDA-MB-231 cells. Conclusions: Consequently, rutaecarpine has a potential therapeutic effect on breast cancer. However, the effectiveness of rutaecarpine is dependent on the subtype of breast cancer.